Sequential triple combo therapy for hypertension in Korean adults
Official title: A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Run by Hanmi Pharmaceutical Company Limited · NCT07784296 · Data updated 2026-11-12
This study tests whether taking amlodipine/losartan/chlorthalidone in sequence helps Korean adults with high blood pressure feel better and stay safe.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 3500 (estimated) |
| Sponsor | Hanmi Pharmaceutical Company Limited Industry-sponsored |
| Locations | 1 site (Gyeonggi-do) |
| Status | Recruiting |
| Started | March 19, 2026 |
| Main results expected | August 31, 2028 |
| Study ends | August 31, 2028 |
| Registry record updated | August 25, 2026 |
| Trial ID | NCT07784296 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Korean adults aged 19 and older with hypertension, either newly diagnosed or on a single antihypertensive drug, for whom a physician deems Amoprel therapy appropriate and who consent to participate.
✕Probably not a fit
Patients who do not respond to the therapy or who experience adverse events may not see a benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, prospective, non-interventional study conducted in Korea to observe the effectiveness and safety of sequential triple therapy with amlodipine, losartan, and chlorthalidone in adults with hypertension. Participants may be newly diagnosed or already on a single antihypertensive drug, with treatment decisions guided by physicians. The study collects real-world data on how well the regimen lowers blood pressure and what adverse events may occur, without random assignment or imposed interventions. Data will be analyzed to describe overall outcomes and safety signals in routine clinical practice. Lead sponsor is Hanmi Pharmaceutical, with the study conducted at Yongin Severance Hospital and collaborating sites as applicable.
Why it matters
Potential benefit: If successful, patients may achieve better blood pressure control with an understood safety profile using this sequential combination therapy.
How similar studies have gone: Previous observational experiences with combination antihypertensive regimens have demonstrated potential improvements in blood pressure control in real-world settings, though this specific sequential triple therapy approach is being explored observationally.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Korean patients aged 19 years or older diagnosed with hypertension 2. Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug 3. Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment 4. Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study Exclusion Criteria: 1. Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab. 2. Pregnant women, women who may be pregnant, and nursing mothers 3. Individuals currently participating in an interventional study 4. Individuals deemed unsuitable for participation in this study by the researcher for other reasons
Where it's running
-
Yongin Severance Hospital
Gyeonggi-do, South Korea Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using low-dose aspirin after preeclampsia to improve recovery
This study is testing if taking low-dose aspirin for six months after having preeclampsia can help new moms recover better by improving their blood pressure and blood vessel function.
-
IMB-guided health education to boost medication taking and blood pressure control in adults with hypertension
This study tests a health-literacy program based on Information-Motivation-Behavioral Skills to help adults with hypertension who don’t take their medicines regularly to take them more consistently and better control their blood pressure.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Hypertension: Does Education Help Patients Manage Blood Pressure Better?
This study tests whether structured patient education improves blood pressure control and self-management in adults with hypertension who speak Turkish.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Long-term GW906 treatment for people with essential hypertension
This trial tests whether long-term GW906 injections are safe and effective for adults with essential hypertension who completed an earlier GW906 study.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.